MariMed Inc. transitioned from an advisory firm to a multi-state vertically integrated cannabis operator with 33 licenses across six states, generating revenue growth averaging 11.6% through 2020. Its portfolio of proprietary brands underpins wholesale and retail expansion via its Thrive™ dispensaries, contributing to market differentiation amid fierce competition. However, persistent federal Schedule I classification imposes tax penalties and legal uncertainty, which alongside rising operating losses despite strong cash flow, tempers near-term profitability. The company’s capital deployment shows prudence with sharply reduced capex and robust operating cash flow supporting liquidity but no shareholder returns yet. Rescheduling efforts and licensing dynamics will be pivotal for future growth trajectories.